• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Kennedy Lawrence T. Jr bought $40,562 worth of shares (35,000 units at $1.16) (SEC Form 4)

    11/22/24 12:30:13 PM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Kennedy Lawrence T. Jr

    (Last) (First) (Middle)
    1700 MADISON ROAD, SUITE 200

    (Street)
    CINCINNATI OH 45206

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIODESIX INC [ BDSX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/21/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/21/2024 P 35,000 A $1.1589(1) 10,411,024 I By: Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01
    Common Stock 12,267,873 I By: Lawrence T. Kennedy, Jr. Perpetuity Trust UAD 6/30/16
    Common Stock 2,775,386 I By: KFDI-B LLC
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.155 to $1.1602, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
    /s/ Robin H. Cowie as Attorney-in-Fact for Lawrence T. Kennedy, Jr. 11/22/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BDSX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

      LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the Ame

      6/10/25 6:17:00 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

      LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center. The Ver

      5/22/25 5:03:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix to Participate in Upcoming Investor Conferences

      LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference 1x1 MeetingsDate: Wednesday, May 28, 2025 Location: Minneapolis, MN 45th Annual William Blair Growth Stock Conference Presentation and 1x1 Meetings Date and Time: Wednesday, June 4, 2025 at 9:20 AM CTLocation: Chicago, IL The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodes

      5/21/25 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schuler Jack W bought $1,316,624 worth of shares (4,723,239 units at $0.28) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      5/20/25 4:11:31 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Director Schuler Jack W bought $122,840 worth of shares (100,000 units at $1.23) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      11/22/24 12:30:34 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Director Kennedy Lawrence T. Jr bought $40,562 worth of shares (35,000 units at $1.16) (SEC Form 4)

      4 - BIODESIX INC (0001439725) (Issuer)

      11/22/24 12:30:13 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    See more
    • Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

      Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

      12/16/22 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

      Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

      12/8/21 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Strobeck Matthew

      4 - BIODESIX INC (0001439725) (Issuer)

      5/22/25 4:16:43 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Chairman Patience John

      4 - BIODESIX INC (0001439725) (Issuer)

      5/22/25 4:16:29 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Massarany Hany

      4 - BIODESIX INC (0001439725) (Issuer)

      5/22/25 4:16:13 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    SEC Filings

    See more
    • SEC Form S-8 filed by Biodesix Inc.

      S-8 - BIODESIX INC (0001439725) (Filer)

      5/30/25 4:10:49 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Biodesix Inc.

      8-K - BIODESIX INC (0001439725) (Filer)

      5/21/25 4:43:05 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Biodesix Inc.

      SCHEDULE 13D/A - BIODESIX INC (0001439725) (Subject)

      5/20/25 4:11:48 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Biodesix downgraded by William Blair

      William Blair downgraded Biodesix from Outperform to Mkt Perform

      5/14/25 8:54:25 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Scotiabank initiated coverage on Biodesix

      Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

      9/16/24 8:45:16 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Craig Hallum initiated coverage on Biodesix with a new price target

      Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

      7/26/24 7:48:11 AM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

      SC 13G/A - BIODESIX INC (0001439725) (Subject)

      11/13/24 7:30:22 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Biodesix Inc.

      SC 13G - BIODESIX INC (0001439725) (Subject)

      6/24/24 12:16:38 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

      SC 13D/A - BIODESIX INC (0001439725) (Subject)

      5/23/24 7:10:37 PM ET
      $BDSX
      Medical Specialities
      Health Care

    $BDSX
    Financials

    Live finance-specific insights

    See more
    • Biodesix Announces First Quarter 2025 Results and Highlights

      Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. "Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline," said Sc

      5/13/25 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

      LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the

      4/29/25 6:00:00 AM ET
      $BDSX
      Medical Specialities
      Health Care
    • Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

      Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). "Biodesix concluded a strong 2024, advancing our key initiatives and delivering on our financial and operational goals," said Scott Hutton, Chief Executive Officer. "We exceeded our revenue targets, with total revenue re

      3/3/25 4:01:00 PM ET
      $BDSX
      Medical Specialities
      Health Care